Drugs / LY3463251
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03764774 | Dec 2018 → Dec 2020 | — | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3463251 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03764774 ↗ |
| Action | Activate | “a potent agonist at the GFRAL/RET receptor” PMID 36630958 ↗ Jan 2023 |
| Route | Subcutaneous | “when it is administered subcutaneously (under the skin) into the abdomen.” NCT03764774 ↗ |
| Target | GFRAL | “a potent agonist at the GFRAL/RET receptor” PMID 36630958 ↗ Jan 2023 |
| Target | RET | “a potent agonist at the GFRAL/RET receptor” PMID 36630958 ↗ Jan 2023 |